Blue Earth Diagnostics doses first patient in Phase 3 LIGHTHOUSE clinical trial
UK-based molecular imaging company Blue Earth Diagnostics has announced dosing of first patient in its Phase 3 LIGHTHOUSE clinical trial of targeted PET imaging agent rhPSMA-7.3 (18F) in